The purpose of this study was to investigate the effect and selectivity of an extract of Schisandra chinensis berries against Chlamydia pneumoniae and C. trachomatis. Among the ethnopharmacological uses of the extract from Schisandrae fructus are cough and pneumonia. Therefore we focused on respiratory pathogens. The extract completely inhibited the growth of C. pneumoniae strain CV6 at 250 µg/mL concentration. The inhibition of C. pneumoniae and C. trachomatis growth was dose dependent and established with three different strains. The extract inhibited C. pneumoniae production of infectious progeny in a dose dependent manner. Chlamydia selectivity was elucidated with growth inhibition measurements of three other respiratory bacterial species. A pure compound found in Schisandra chinensis berries, schisandrin B at 20.0 µg/mL concentration inhibited the growth of both C. pneumoniae and C. trachomatis. The extract was found to be non-toxic to the human host cells. These findings highlight the potential of the extract from Schisandra chinensis berries as a source for antichlamydial compounds.
The plant family Schisandraceae comprises two genera, Kadsura and Schisandra, in which the genus Schisandra includes 10 species with their varieties [1] . The major and characteristic constituents of Schisandraceae plants are lignans, including dibenzocyclooctadiene lignans [2] . Although Schisandra plants share a number of common chemical compounds, the spectrum of lignans varies remarkably among the different species.
In traditional Chinese medicine, S. chinensis has commonly been used for the treatment of hepatic disease and for liver protection [3] . Recent studies have shown that the lignans of S. chinensis berries have various pharmacological activities, such as neuro-, cyto-and hepatoprotective, as well as anti-inflammatory and antioxidative effects [4a-4c] . In the Chinese Pharmacopoeia one of the common uses for S. chinensis berries (Schisandrae chinensis fructus) is for the treatment of chronic cough [5] . A clinical study suggests that a tincture of Schisandra fruit has alleviating effects on the symptoms of pneumonia [6] . Earlier clinical investigations made in the USSR show a reduced prevalence of influenza in study subjects taking Schisandra tincture [7] .
Dibenzocyclooctadiene lignans from plants in the genus Schisandra have been shown to possess various anti-viral activities, including anti-HIV activity [8a-8c], inhibition of HSV-2 and adenovirus [9] , and inhibition of Epstein-Barr virus early antigen activation [10] . Despite the wide-ranging activity of Schisandra lignans against different viruses, the antibacterial activity of S. chinensis lignans has not been reported.
The genus Chlamydia includes obligate intracellular bacteria, which have a biphasic developmental cycle of replication. The forms outside the host cells are metabolically inactive elementary bodies (EBs). Intracellular metabolically active forms instead are known as reticulate bodies (RBs). EBs enter the host cells inside phagosomes. These contain the chlamydial particles in their different phases of development. This chlamydial phagosome is termed inclusion. Two species, C. pneumoniae and C. trachomatis are the most prominent Chlamydiales in humans, with C. pneumoniae being the more common of these two. C. pneumoniae is a causative agent of a number of respiratory tract illnesses including community-acquired pneumonia (reviewed in Hanski & Vuorela [11a] and Hahn et al.
[11b]. Acute C. pneumoniae infection has also been implicated with chronic respiratory diseases including asthma, chronic bronchitis and chronic obstructive pulmonary disease (COPD). Under some yet unknown conditions C. pneumoniae can turn into a persistent form within the host. This chronic form has been associated with a variety of chronic diseases including the above mentioned respiratory tract illnesses, atherosclerosis, reactive arthritis, Alzheimer's disease and lung cancer [12a, b, c] .
Despite the good response of C. pneumoniae to several antibiotics, treatment failures are a matter of concern. The risk of infection relapsing and turning into a persistent state remains as a major challenge [11a,13a, b, c] . Clearly there is a demand for further research and development of new antibiotics for the treatment of chlamydial infections. Thus, the aim of this study was to elucidate the antichlamydial activity of a dibenzocyclooctadiene lignancontaining extract of S. chinensis berries against C. pneumoniae. The antichlamydial activity of the extract was studied with two clinical strains, K7 (Kajaani 7; respiratory tract origin) and CV6 (cardiovascular origin). Selectivity was further studied with another clinically important species, C. trachomatis.
The acute infection cycle of C. pneumoniae is 72 hours. In in vitro experiments this is termed as first passage. Then the infectious elementary bodies are released from the host cells to infect new host cells, and the cycle begins again (second passage). The bulk of EBs produced within this second cycle of infection is the infectious progeny. The impact of the inhibitory activity on C. pneumoniae production of infectious progeny was studied with the extract. In the current study we report, for the first time, the antichlamydial activity of an aqueous methanol extract of S. chinensis berries. In the chlamydia inhibition assays, HL (human line, respiratory origin) cells were infected with C. pneumoniae strains. HeLa cells were infected with C. trachomatis strain L2. The chlamydia inhibition in this context is referred to as decrease in inclusion counts. The extract was administered to the infected cells at final concentrations of 10, 25, 50, 100 and 250 µg/mL in each bacterial growth inhibition experiment. Schisandra extract had a MIC-value of < 100 µg/mL against C. pneumoniae strains CV6 and K7, whereas the value for C. trachomatis exceeded 250 µg/mL. The extract showed inhibition in a dose-dependent manner (Figure 1 ). The estimated IC 50 -values for the extract against C. pneumoniae were 36.4 and 54.2 µg/mL for K7 and CV6, respectively (Table 1) . There was no statistically significant difference between the dose responses of K7 and CV6 either at the first or second passage.
At the first passage of the infection the inhibition percentages of the extract ranged from 0.54 to 98.7% for K7 and from 18.4 to 100.0% for CV6. The corresponding inhibition percentages at the second passage were 26.9 to 100.0% and -12.7 to 100.0% (Figure 1 ). Schisandra extract inhibited also the second passage at the assayed concentrations of ≥ 50 µg/mL, P < 0.01 -0.001, with both C. pneumoniae strains. This indicates that the extract inhibits the replication of chlamydia so that the production of a second passage is also inhibited.
The pure compounds schisandrin and schisandrin B, present in S. chinensis fruits (S1), inhibited both C. pneumoniae and C. trachomatis, with the former being more susceptible to schisandrin B with an over two-fold lower IC 50 -value (Table 1 ). According to HPLC analysis of the powdered berries, the content of schisandrin was 0.5% and the content of schisandrin B was 0.4%. The contents of other lignans present in the berries, namely schisandrin A, schisanterin A and schisandrin C, were 0.2%, 0.1% and 0.1%, respectively, and were of the same level as reported earlier [14] . The two major lignans present in the berries, schisandrin and schisandrin B showed a notable inhibition of all the chlamydial strains, with the latter being a remarkably more active inhibitor of chlamydial growth. These findings, however, do not exclude the possibility of other compounds in the extract having antichlamydial potency.
To examine the chlamydia-selectivity of the extract, the inhibition was measured of Gram-positive Streptococcus pneumoniae and S. pyogenes, as well as Gram-negative Klebsiella pneumoniae. These pathogens typically cause respiratory tract diseases, including pneumonia. Inhibition assays were also performed with pure lignan compounds ( Figure 2 ) present in S. chinensis fruits (S1). Neither the extract nor the pure compounds had any inhibitory effect on the other studied bacteria (Table 1) , indicating a degree of selectivity of the antichlamydial effect.
Schisandra extract is commonly and widely used in Traditional Chinese Medicine and has been evaluated in clinical studies [15] . The toxicity of the extract has been studied in numerous in vitro as well as in vivo studies, and it has been shown to be non-toxic. Also, our results support this, as the viability of the 250 µg/mL Schisandra extract treated human host cells was 90.3% for the confluent cells and 97.3% for the growing cells, with no statistically significant difference from the non-treated controls.
Taken together, the results presented herein suggest that Schisandra extract and its lignan compounds have great potential for a broad antichlamydial activity, whereas other respiratory bacteria are not susceptible to them.
Experimental
General: Turbidity and fluorescence measurements were obtained with a VarioSkan Flash plate reader (Thermo Fischer Scientific, Vantaa, Finland). Chlamydial inclusions were stained with a FITCconjugated genus-specific anti-LPS antibody Pathfinder (Bio-Rad Laboratories, Inc.) and inclusion counts were determined with a Nikon Eclipse 300 (Nikon, Tokyo, Japan) fluorescent microscope with a 200 × magnification. For TLC, reference solutions were Antichlamydial activity of Schisandra chinensis Natural Product Communications Vol. 10 (6) 2015 1003 applied to silica plates (TLC silica gel 60 F 254 , Merck, Germany) with a semi-automatic applicator (Camag Linomat IV, Germany). The plate was documented with a camera (Camag Reprostar 3, Germany). For HPLC analysis, a 250 × 4.6 mm Supelco Discovery C18 column with a particle size of 5 μm was used.
Preparation of the Schisandra extract and pure compounds:
The powdered berries of S. chinensis were purchased from Loitsukeller, Estonia. Their identity and schisandrin content were investigated by TLC and HPLC according to European Pharmacopoeia guidelines [16] . The extract was prepared in the following manner: 100 mL of 80% aqueous methanol (HPLC grade, Rathburn Chemicals Ltd., Walkerburn, Scotland) was added to 5.0 g of finely powdered S. chinensis berries. This mixture was sonicated for 10 min at room temperature and vacuum-filtered using Whatman No 1 filter paper (Springfield Mill, Maidstone, Kent, England). The extract was evaporated to dryness using a rotary evaporator (Heidolph VV200, Germany). The residue was dried under N 2 flow and frozen at -20°C overnight. The frozen extract was lyophilized (LyoPro 3000, Heto Holten A/S, Denmark) for 5 days. 
Cell lines and infection with Chlamydiae:
Human epithelial HL cells (respiratory origin) for infections with C. pneumoniae were grown in RPMI-1640 medium supplemented with 2 mM L-glutamine, 7.5% FBS and 20 µg/mL gentamicin, at 37°C, 5% CO 2 and 95% humidity to confluence in cell culture flasks. HeLa-229 cells (CCL-2.1; ATCC, Manassas, VA, USA) for the infections with C. trachomatis were grown in RPMI-1640 medium supplemented with 10% FBS, 20 mM HEPES (pH 8.0), 8 µg/mL gentamicin, 1 µg/mL amphotericin B and 2 mM L-glutamine at 37°C, in a humified atmosphere in 5% CO 2 . HL cells were infected with C. pneumoniae clinical strains K7 and CV6, and the effects of the extract and lignans on the C. pneumoniae inclusion counts after 72 h infection were determined as described [17] , using an immunofluorescent antibody. C. trachomatis serovar L2 (VR-902B; ATCC) inclusion counts in HeLa cells were determined with a similar method after 24 h infection.
The production of infectious progeny was assayed with C. pneumoniae strains K7 and CV6, as described earlier [18] , with slight modifications. Infected cell cultures exposed to the extract were lysed at 72 h and were used to inoculate fresh HL cells. With both passages, the infected cells were fixed and stained to determine the amount of infectious progeny.
Host cell viability assay and chlamydia selectivity:
Extract treated HL and HeLa cell viability was confirmed by resazurin assay. The cells were seeded into a 96-well plate to a density of 5 × 10 3 (growing) and 6 × 10 4 cells (confluent) per well. After overnight incubation the medium was changed to a fresh medium containing the studied compounds and the extract together with a positive control Triton X. Concentration of DMSO in all the wells was adjusted to 0.25%. After 72 h exposure at 37°C in 5% CO 2 , the cells were treated with a profluorescent probe, resazurin. The fluorescence was measured at 570/590 nm (ex/em).
Growth inhibition of other bacteria was studied in order to investigate chlamydial selectivity of the extract and lignans. These Gram-positive and Gram-negative bacteria were Streptococcus pneumoniae (DSM 11867, DSMX Collections), S. pyogenes (ATCC; 12351) and Klebsiella pneumoniae (HAMBI culture collection; 1332). K. pneumoniae was grown in nutrient broth and Streptococci in Todd-Hewitt broth. As negative controls 20 µM ampicillin and rifampicin were used; non-treated bacteria and broth served as positive controls and broth as a blank. The amount of DMSO was adjusted to the same concentration in each well. Growth inhibition of other bacteria was investigated by turbidity measurements and resazurin staining of metabolically active bacteria [19] .
